<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002829</url>
  </required_header>
  <id_info>
    <org_study_id>DM94-009</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-94009</secondary_id>
    <secondary_id>NCI-G96-0994</secondary_id>
    <secondary_id>CDR0000065027</secondary_id>
    <nct_id>NCT00002829</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplantation in Treating Patients With Lymphoma</brief_title>
  <official_title>Autologous and Allogeneic Bone Marrow Transplantation for Low Grade Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer
      cells, and may be an effective treatment for lymphoma. Bone marrow transplantation may be
      able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to
      kill cancer cells.

      PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating
      patients with recurrent or residual low-grade lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Examine the potential role of high dose etoposide, cyclophosphamide, total
      body irradiation and bone marrow transplantation for patients at high risk for disease
      progression. II. Determine the value of monitoring the quality of remission by PCR assessment
      of BCl-2. III. Evaluate the efficacy of alpha interferon for patients with evidence of
      residual or recurrent lymphoma. IV. Evaluate the efficacy of bone marrow purging by PCR
      assessment of BCl-2.

      OUTLINE: Patients receive a brief 2-3 cycles of intensive chemotherapy to achieve minimum
      disease state. Etoposide is administered intravenously on day -8. Cyclophosphamide is infused
      intravenously over 2 hours daily on day -7 and -6. Patients receive mesna beginning 1 hour
      after initiation of the cyclophosphamide treatment. Total body irradiation is received on
      days -4, -3, -2 , and -1. On day 0 allogeneic or autologous bone marrow is infused
      intravenously. Patients with residual or recurrent lymphoma receive interferon alpha daily.

      PROJECTED ACCRUAL: 35 allogeneic and 40 autologous patients are expected to be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1994</start_date>
  <completion_date type="Actual">April 2002</completion_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Response</measure>
    <time_frame>2 Years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Bone Marrow Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Interferon Alfa</intervention_name>
    <description>Daily</description>
    <arm_group_label>Bone Marrow Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Infused intravenously over 2 hours daily on Day -7 and -6.</description>
    <arm_group_label>Bone Marrow Transplantation</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Administered intravenously on Day -8</description>
    <arm_group_label>Bone Marrow Transplantation</arm_group_label>
    <other_name>VePesid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Beginning 1 hour after initiation of the cyclophosphamide treatment.</description>
    <arm_group_label>Bone Marrow Transplantation</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Transplantation</intervention_name>
    <description>Infusion on Day 0.</description>
    <arm_group_label>Bone Marrow Transplantation</arm_group_label>
    <other_name>BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Total body irradiation is received on days -4, -3, -2 , and -1.</description>
    <arm_group_label>Bone Marrow Transplantation</arm_group_label>
    <other_name>RT</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>TBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven low grade lymphoma in the following
        settings: Consolidation of newly diagnosed stage IV high-risk patients after 6-9 months of
        intensive conventional dose chemotherapy involving doxorubicin High risk is defined as &gt;=5
        cm adenopathy and &gt;=2 extranodal sites at diagnosis, or males with &gt;=5 cm adenopathy and &gt;
        20% marrow infiltrate at diagnosis) Failure to achieve CR within 6 months in newly
        diagnosed patients with intensive doxorubicin treatment Relapse patients who are sensitive
        to doxorubicin or ESHAP chemotherapies Patients with resistant chemotherapy failure
        (allogeneic BMT only) Patients with HLA-identical sibling donors are eligible for
        allogeneic bone marrow transplantation; other patients are eligible for autologous marrow
        transplantation Bone marrow must be in complete or near complete remission (&lt; 15 %
        malignant cells) in autologous transplant patients

        PATIENT CHARACTERISTICS: Age: 15 to 60 years Performance Status: Zubrod 0-2 Hematopoietic:
        Not specified Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater
        than 2.0 mg/dL Cardiovascular: Cardiac ejection fraction at least 50% Pulmonary: DLCO at
        least 50% Other: No concomitant severe medical illnesses No psychosis

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior chemotherapy
        allowed Endocrine therapy: Not specified Radiotherapy: No prior extensive radiotherapy
        Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E. Champlin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2004</study_first_posted>
  <last_update_submitted>July 26, 2012</last_update_submitted>
  <last_update_submitted_qc>July 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma</keyword>
  <keyword>mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

